After FDA Approval For Ovarian Cancer Drug, ImmunoGen Becomes Top Pick For This Analyst

The post After FDA Approval For Ovarian Cancer Drug, ImmunoGen Becomes Top Pick For This Analyst appeared on BitcoinEthereumNews.com.

Tuesday, the FDA granted accelerated approval for ImmunoGen Inc’s (NASDAQ: IMGN) Elahere (mirvetuximab soravtansine-gynx) for folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. HC Wainwright says the approved label does…

Leave a Reply

Your email address will not be published. Required fields are marked *